A pivotal trial of a personalized neoantigen mRNA cancer vaccine combined with Keytruda met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) at a prespecified interim analysis. The combination showed statistically significant and clinically meaningful improvement over Keytruda monotherapy as adjuvant therapy in resected melanoma.
Why it matters: The interim analysis provides RFS and DMFS data readers can compare directly with existing Keytruda monotherapy adjuvant data in resected melanoma.
Moderna's personalized mRNA cancer vaccine met its endpoint in the phase III randomized controlled INTerpath-001 trial. The study enrolled 1,137 patients with stage IIB-IV cutaneous melanoma after complete surgical resection and no prior systemic therapy. It is the first personalized neoantigen therapy to succeed in a phase III randomized controlled trial.
Why it matters: The source gives the 1,137-patient stage IIB-IV post-surgery enrollment range and safety readout for comparison with prior phase II efficacy signals.
Intismeran autogene, a personalized neoantigen mRNA therapy jointly developed by Merck and Moderna, met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) when combined with KEYTRUDA. The results come from INTerpath-001, an international multicenter trial in adjuvant treatment of completely resected stage IIB-IV melanoma.
Why it matters: The brief gives INTerpath-001 topline and primary endpoint data for judging the added benefit of the mRNA neoantigen therapy over KEYTRUDA alone.
Moderna and Merck jointly announced that the Phase III INTerpath-001 trial of the personalized mRNA neoantigen therapy intismeran (V940/mRNA-4157) combined with pembrolizumab as adjuvant therapy for melanoma met positive topline results. Each intismeran course encodes up to 34 neoantigens, tailored to each patient's tumor mutation profile; Moderna shares surged 177% on the news.
Why it matters: Reports the positive INTerpath-001 topline readout and Moderna's 177% share surge as a market reference for personalized mRNA neoantigen therapy in melanoma adjuvant treatment.
Merck and Moderna announced that the Phase III INTerpath-001 trial met both its recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) endpoints. The trial evaluated the personalized cancer vaccine intismeran autogene (V940 or mRNA-4157) combined with KEYTRUDA as adjuvant therapy in patients with fully resected stage IIB–IV melanoma. Moderna shares closed up 176.97% after the announcement.
Why it matters: The trial met both RFS and DMFS endpoints in resected melanoma adjuvant therapy, providing a benchmark for personalized vaccine plus PD-1 regimens.
Moderna's cancer therapy met its primary endpoint of recurrence-free survival (RFS) in the Phase III INTerpath-001 trial, which enrolled 1137 patients with high-risk melanoma. It reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%. On the news, Moderna's stock rose 177% in a single day and Merck's rose nearly 13%.
Why it matters: The brief gives dual endpoint data of a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis risk, plus a 1137-patient sample, directly quantifying efficacy.
FDA has approved OncoSil Medical's phosphorus-32 (P-32) radioactive implant device through the Humanitarian Device Exemption pathway for unresectable, non-metastatic distal bile duct cancer. It is described as the first and so far only Class III medical device approved specifically for this rare, aggressive bile duct cancer subtype. The approval adds a new radiotherapy option delivered via an established isotope rather than newer agents such as lutetium-177 or actinium-225.
On August 19, 2026, Moderna and Merck jointly announced that the INTerpath-001 trial of the personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) combined with Keytruda (pembrolizumab) succeeded. The original article reports Moderna's stock surged 177% that day, calls it an "extraordinary milestone," and says the company's next three years hinge on converting this result into sustainable cash flow.
Carvalho et al. identify spatially organized niches in bladder cancer formed by EMT-like CD44-high cancer cells paired with SPP1/PARP14-high macrophages, and these niches drive chemoresistance. Inhibiting PARP14 converts this protective niche into an inflammatory state and sensitizes tumors to cisplatin.
An interim analysis of the Phase III INTerpath-001 trial, run by Moderna and Merck, met its primary endpoint. Adjuvant treatment with intismeran autogene plus Keytruda improved recurrence-free survival (RFS) in patients with completely resected stage IIB-IV melanoma and met the key secondary endpoint of distant metastasis-free survival (DMFS). The results provide key Phase III evidence for personalized neoantigen vaccines in melanoma adjuvant therapy.
Why it matters: The positive Phase III data validate personalized neoantigen vaccines in melanoma adjuvant therapy and inform extending the mRNA platform to oncology.
The Cancer Dependency Map now includes next-generation cancer models, based on 147 genome-scale CRISPR screens and multi-omic characterizations of organoids and spheroids across 10 cancer types. These models expand coverage to new genomic and molecular subtypes, reveal biomarker-associated vulnerabilities, preserve transcriptional programs silenced in traditional cell lines, and expose how growth format and culture medium affect gene essentiality. The integrated dataset is available through the DepMap portal.
Cold atmospheric plasma reprograms tumor-associated neutrophils by delivering reactive oxygen species and redox cues that inhibit mitophagy, restoring mitochondrial membrane potential and oxidative metabolism, and shifting neutrophils from immunosuppressive to immunostimulatory phenotypes. In syngeneic and humanized bladder cancer models, intravesical CAP reshaped the myeloid landscape, enhanced T cell infiltration, suppressed tumor progression, and sensitized tumors to PD-1 blockade. The findings establish a drug-free, locoregional biophysical way to overcome neutrophil-mediated immune suppression.
AstraZeneca has discontinued the Phase III eVOLVE-Lung02 study of its PD-1/CTLA-4 bispecific antibody Volrustomig as first-line therapy for non-small cell lung cancer. After a pre-specified interim analysis, the independent data monitoring committee concluded the drug was almost certainly unable to beat the standard regimen of pembrolizumab plus chemotherapy in the PD-L1 negative population. The global, multicenter pivotal trial enrolled 895 patients and failed at its first readout.
Why it matters: Provides a Phase III interim failure for a PD-1/CTLA-4 bispecific in first-line NSCLC, with the comparator regimen, as a reference for the same-target pipeline.
BMS has paid Baili Tianheng another $250 million for the bispecific ADC iza-bren, after the drug met its primary progression-free survival endpoint in a Phase III trial in EGFR-mutated non-small cell lung cancer. This is the fourth successful Phase III study for iza-bren and the first positive Phase III evidence for a bispecific ADC in the world's largest cancer. The payment adds to the in-licensing deal BMS struck three years ago, which carried an $800 million upfront payment and a total value of $8.4 billion.
On August 17 local time, EyePoint announced topline results from LUGANO, the first pivotal Phase III study of DURAVYU in wet age-related macular degeneration (wAMD). DURAVYU failed to meet the primary endpoint of non-inferiority to aflibercept in best corrected visual acuity (BCVA). The Phase III result also dragged down two companies based far apart, one described in reports as an oncology giant with a market value of about 20 billion.
Why it matters: The topline result missed the non-inferiority primary endpoint, letting readers assess the competitive landscape for long-acting VEGF agents in wet AMD.
On August 6, 2026, the FDA granted accelerated approval to Replimune's oncolytic virus therapy Tudriqev in combination with a PD-1 inhibitor for patients with PD-1-resistant advanced melanoma. It is the first approved oncolytic virus combination therapy worldwide and the first oncolytic virus approval by the FDA in 11 years.
Moderna and Merck announced that the personalized mRNA neoantigen vaccine intismeran combined with Keytruda met its primary endpoint in a Phase 3 adjuvant melanoma trial, delaying recurrence and distant metastasis. The release did not provide the HR, confidence intervals, or detailed endpoint results; those await a full readout and comparison with existing adjuvant immunotherapy regimens.
Why it matters: Topline result for a personalized mRNA vaccine plus Keytruda in adjuvant melanoma, but HR, confidence intervals, and stratification details were not released, so it serves only as a preliminary reference for Phase 3 neoantigen vaccine readouts.
The paper reports a strategy for enhancing the antitumor immunity of mRNA vaccines using bioorthogonal-like delayed activation of exogenous STING. The approach delays STING activation so that it coincides with vaccine-induced antigen expression rather than acting immediately on delivery. No results or quantitative outcomes are stated in the material itself.
Merck and Moderna's personalized mRNA cancer vaccine, combined with Keytruda, met the primary endpoint of recurrence-free survival in a phase 3 trial in high-risk skin cancer, positioning the partners to potentially seek accelerated approval.
Subclinical cholestasis emerges as a hallmark of gut dysbiosis that drives resistance to PD-1 blockade. Antibiotics or Enterocloster species depleted secondary bile acids such as deoxycholic acid and raised tauro-conjugated primary bile acids in plasma; restoring bile acid balance with FMT, fexaramine, or GDCA circumvented primary resistance to PD-1 blockade. Elevated γ-glutamyl transferase predicted poor survival in multivariate analyses across six immunotherapy cohorts.
